Clinical pharmacology and therapeutics of antidepressants

Pharmacotherapy of Depression: Second Edition

Volumn , Issue , 2011, Pages 33-124

  Ciraulo, Domenic A ^a   Shader, Richard I ^b   Greenblatt, David J ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39449112282     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-435-7_2     Document Type: Chapter

References (408)

1. Mrazek D. Psychiatric pharmacogenomics. Oxford: Oxford University Press; 2010.
2. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009;124(1):57-73.
3. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57(2):203-9.
4. Pariante CM. Glucocorticoid receptor function in vitro in patients with major depression. Stress. 2004;7(4):209-19.
5. Pariante CM. The role of multi-drug resistance p-glycoprotein in glucocorticoid function: studies in animals and relevance in humans. Eur J Pharmacol. 2008;583(2-3):263-71.
6. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319-25.
7. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res. 2004;38(6):577-82.
8. Hawley CJ, Gale TM, Sivakumaran T. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002;72(2):177-84.
9. Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics. 2008;9(7):841-6.
10. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009;9(4):225-33.
11. Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104(1-3):83-90.
12. Tsai SJ, Hong CJ, Chen TJ, Yu YW. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(8):1097-8.
13. Ising M, Depping AM, Siebertz A, Lucae S, Unschuld PG, Kloiber S, et al. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci. 2008;28(2):389-98.
14. Laje G, Perlis RH, Rush AJ, McMahon FJ. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv. 2009;60(11):1446-57.
15. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181-8.
16. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35(3):727-40.
17. Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34(10):2227-36.
18. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966-75.
19. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet. 2009;373(9665):746-58.
20. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
21. Dunner DL. Acute and maintenance treatment of chronic depression. J Clin Psychiatry. 2001;62(Suppl 6):10-6.
22. Stewart JW, McGrath PJ, Quitkin FM. Can mildly depressed outpatients with atypical depression benefit from antidepressants? Am J Psychiatry. 1992;149(5):615-9.
23. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackiem HA, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26(2):457-94.
24. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200.
25. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52(Suppl):28-34.
26. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-47.
27. Kennedy N, Abbott R, Paykel ES. Longitudinal syndromal and sub-syndromal symptoms after severe depression: 10-year follow-up study. Br J Psychiatry. 2004;184:330-6.
28. Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on longterm outcome. J Affect Disord. 2004;80(2-3):135-44.
29. Kennedy N, Paykel ES. Treatment and response in refractory depression: results from a specialist affective disorders service. J Affect Disord. 2004;81(1):49-53.
30. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry. 1998;59(Suppl 20):85-93.
31. Ban TA. Pharmacotherapy of depression: a historical analysis. J Neural Transm. 2001;108(6):707-16.
32. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60(Suppl 4):4-11; discussion 2-3.
33. Sampson SM. Treating depression with selective serotonin reuptake inhibitors: a practical approach. Mayo Clin Proc. 2001;76(7):739-44.
34. Goldberg JF. New drugs in psychiatry. Emerg Med Clin North Am. 2000;18(2):211-31; viii.
35. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J Psychopharmacol. 1998;12(3 Suppl B):S5-20.
36. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology. 1992;31(10):997-1000.
37. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr. 2002;7(Suppl 1):40-4.
38. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Therap. 2003;305(1):197-204.
39. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 2000;22(4):380-7.
40. Uhr M, Graucer MT. abc1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res. 2003;37:179-85.
41. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001;41(7):708-14.
42. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160(4):734-40.
43. Goodwin GM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry. 1996;57(Suppl 4):9-13.
44. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in p atients with major depression treated with paroxetine. Am J Psychiatry. 2002;159(10):1702-10.
45. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatment: implications for the therapeutic response in major depression. J Clin Psychopharmacol. 1987;7:24S-35.
46. Banasr M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 2004;29(3):450-60.
47. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology. 2009;34(11):2459-68.
48. Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol. 2009;9(1):24-30.
49. Benamansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci. 2002;22(15):6766-72.
50. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51(3):248-51.
51. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15(3):217-22.
52. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154(12):37-43.
53. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebocontrolled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349(9065):1594-7.
54. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol. 1999;19(2):177-82.
55. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158(10):1725-7.
56. Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry. 2001;158(12):2080-2.
57. Wu S, Comings DE. A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet. 1999;9(2):105-6.
58. Nishiguchi N, Shirakawa O, Ono H, Nishimura A, Nushida H, Ueno Y, et al. Lack of an association between 5-HT1A receptor gene structural polymorphisms and suicide victims. Am J Med Genet. 2002;114(4):423-5.
59. Isaac MT, Tome MB. Pindolol-paroxetine combination. Am J Psychiatry. 1997; 154(12):1790-1.
60. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry. 1998;59(Suppl 5):16-23.
61. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry. 1998;155(10):1346-51.
62. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Br J Psychiatry. 1995;167(5):575-80.
63. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry. 1996;57(Suppl 8):17-25.
64. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3):311-20.
65. Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol. 1998;13(Suppl 5):S35-43.
66. Baker GB, Fang J, Sinha S, Coutts RT. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev. 1998;22(2):325-33.
67. Johnson MD, Newkirk G, White JR, Jr. Clinically significant drug interactions. Postgrad Med. 1999;105(2):193-5, 200, 5-6 passim.
68. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry. 1990;51(Suppl B):9-12.
69. Frazer A. Antidepressants. J Clin Psychiatry. 1997;58(Suppl 6):9-25.
70. Benbow SJ, Gill G. Drug points: paroxetine and hepatotoxicity. Br Med J. 1997;314(7091):1387.
71. Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, et al. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc. 1999;74(7):692-4.
72. Garcia-Pando A, Garcia del Pozo J, Sanchez A, et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry. 2002;63:135-7.
73. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998;12(2):192-214.
74. Walsh MT, Dinan TG. Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand. 2001;104(2):84-91.
75. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997;17(5):377-89.
76. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164(4):549-50.
77. Stoll AL, Mayer PV, Kolbrener M, Goldstein E, Suplit B, Lucier J, et al. Antidepressantassociated mania: a controlled comparison with spontaneous mania. Am J Psychiatry. 1994;151(11):1642-5.
78. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147(2):207-10.
79. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry. 1991;51:267-85.
80. Tollefson GD, Rampey AH, Jr., Beasley CM, Jr., Enas GG, Potvin JH. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. Journal of Clinical Psychopharmacology. 1994;14(3):163-9.
81. Muller-Oerlinghausen B, Berghofer A. Antidepressants and suicidal risk. J Clin Psychiatry. 1999;60(Suppl 2):94-9; discussion 111-6.
82. Tueth MJ. Revisiting fluoxetine (Proxac) and suicidal preoccupations. J Emerg Med. 1994;12(5):685-7.
83. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-13.
84. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17(3):208-21.
85. Dams R, Benijts TH, Lambert WE, Van Bocxlaer JF, Van Varenbergh D, Van Peteghem C, et al. A fatal case of serotonin syndrome after combined moclobemide and citalopram intoxication. J Anal Toxicol. 2001;25(2):147-51.
86. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS. 2001;15(10):1281-5.
87. Holsboer F. Neuroendocrinology of mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven; 1995. p. 957-69.
88. Inder WJ, Prickett TC, Mulder RT, Donald RA, Joyce PR. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology (Berl). 2001;156(1):73-8.
89. Barclay TS, Lee AJ. Citalopram-associated SIADH. Ann Pharmacother. 2002;36:1558-63.
90. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156(8):1170-6.
91. Harvey BH, Bouwer CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol. 2000;23(2):90-7.
92. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):37-41.
93. Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996;30:1232-4.
94. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47-59.
95. Balon R, Yeragani VK, Pohl R, et al. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry. 1993;54:209-12.
96. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry. 1994;55(9):406-13.
97. Margolese HC, Assalian P. Sexual side effects of antidepressants: a review. J Sex Marital Ther. 1996;22(3):209-17.
98. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67-85.
99. Fava M, Rankin MA. Sexual functioning and SSRIs. J Clin Psychiatry. 2002;63(Suppl 5): 13-6.
100. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176-94.
101. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. Fluoxetineinduced sexual dysfunction. J Clin Psychiatry. 1990;51(1):25-7.
102. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1993;54(2):71.
103. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry. 2000;61(Suppl 11): 28-36.
104. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenfalin in antidepressant-induced sexual dysfunction. Psychother Psychosom. 1998;67(6):328-31.
105. Nurnberg HG, Lauriello J, Hensley PL, Parker LM, Keith SJ. Sildenafil for sexual dysfunction in women taking antidepressants. Am J Psychiatry. 1999;156(10):1664.
106. Nurnberg HG, Seidman SN, Gelenberg AJ, Fava M, Rosen R, Shabsigh R. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology. 2002;60(2 Suppl 2):58-66.
107. Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;54(12):459-65.
108. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995;152(10):1514-6.
109. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol. 1998;12(3):305-13.
110. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic critieria. J Psychiatr Neurosci. 2000;25(3):255-61.
111. DeBattista C, Schatzberg AF. Physical sysmptoms associated with paroxetine withdrawal [letters to the editor]. Am J Psychiatry. 1995;152(8):1235-6.
112. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59(Suppl 15):42-8.
113. Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet. 1996;348(9023):339-40.
114. Glassman AH. Citalopram toxicity. Lancet. 1997;350:818.
115. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279(8):609-10.
116. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18-27.
117. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008;83(1):68-76.
118. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. 2010;125(3):e600-8.
119. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn, N Engl J Med. 2006, 354 6, 579-87
120. Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry. 2000;61(11):821-7.
121. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(Suppl 14):39-47.
122. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry. 1999;60(2):101-6.
123. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995;167(3):374-9.
124. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152(9):1368-71.
125. Davidson JRT. Pharmacology of social anxiety disorder. J Clin Psychiatry. 1998;59(Suppl 17): 47-51.
126. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double- blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63(1):66-74.
127. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo- controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990;147(7):876-81.
128. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. New Engl J Med. 1995;332(23):1529-34.
129. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(5):350-7.
130. Davidson JRT. Biological therapies for posttraumatic stress disorder: an overview. J Clin Psychiatry. 1997;58(9):29-32.
131. Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs. 2001;61(1):81-110.
132. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Jr., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-9.
133. Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry. 2001;62(Suppl 20):26-31.
134. Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 2001;21(2):143-53.
135. Davis JM, Wang Z, Janicak PG. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull. 1993;129:175-81.
136. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry. 2000;157(3):344-50.
137. Kasper S, Fuger J, Moller HJ. Comparative efficacy of antidepressants. Drugs. 1992;43(Suppl 2): 11-23.
138. Amsterdam JD. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol. 1998;12(3 Suppl B):S99-111.
139. Verkes RJ, Van der Mast RC, Hengeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry. 1998;155(4):543-7.
140. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry. 1998;59:279-88.
141. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry. 1995;56(2):52-5.
142. Kuhn R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry. 1958;115:459-64.
143. Klerman GL, Cole JP. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev. 1965;17:101-41.
144. Frommer DA, Kulig KW, Marx JA, Rumack B. Tricyclic antidepressant overdose. A review. JAMA. 1987;257(4):521-6.
145. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19(3):373-409.
146. Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG. Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry. 1992;31(4):691-8.
147. Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, et al. A Double- Blind, Placebo-Controlled Trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167:668-75.
148. Blackwell B. Adverse effects of antidepressant drugs; part 1: MAOIs and tricyclics. Drugs. 1981;21:201-19.
149. Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowers MB, Jr. Major adverse reactions during desipramine treatment: relationship to plasma drug concentrations, concomitant antipsychotic treatment, and patient characteristics. Arch Gen Psychiatry. 1982;39(9):1055-61.
150. Glassman AH, Bigger JT, Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry. 1981;38(7):815-20.
151. Glassman AH. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol. 1998;13(Suppl 5):S25-30.
152. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry. 1994;55(Suppl A):83-7; discussion 8-9, 98-100.
153. Vohra J, Burrows GD, Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust N Z J Med. 1975;5(1):7-11.
154. Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB. Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference. J Clin Psychopharmacol. 1981;1(5):316-9.
155. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol. 2003;23(1):58-77.
156. Maltzberg B. Mortality among patients with involutional melancholia. Am J Psychiatry. 1937;93:1231-8.
157. Williams RB, Jr., Sherter C. Cardiac complications of tricyclic antidepressant therapy. Ann Intern Med. 1971;74(3):395-8.
158. Bigger JT, Jr., Giardina EGV, Perel JM, Kantor SJ, Glassman AH. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med. 1977;296(4):206-8.
159. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry. 1987;44(3):273-5.
160. Dalack GW, Roose SP, Glassman AH. Tricyclics and heart failure. Am J Psychiatry. 1991;148(11):1601.
161. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-12.
162. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227-33.
163. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Is doxepin a safer tricyclic for the heart? J Clin Psychiatry. 1991;52(8):338-41.
164. Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT. Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial. Br J Psychiatry. 1987;151:107-12.
165. Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emerg Med. 1985;14:1-9.
166. Kulig K, Rumack BH, Sullivan JB, Jr., Brandt H, Spyker DA, Duffy JP, et al. Amoxapine overdose. Coma and seizures without cardiotoxic effects. JAMA. 1982;248(9):1092-4.
167. Litovitz TL, Troutman WG. Amoxapine overdose. Seizures and fatalities. JAMA. 1983;250(8):1069-71.
168. Knudsen K, Heath A. Effects of self poisoning with maprotiline. Br Med J (Clin Res Ed). 1984;288(6417):601-3.
169. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry. 1993;150(4):571-7.
170. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br J Psychiatry. 2001;178:129-44.
171. Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Aust N Z J Psychiatry. 1999;33:323-7.
172. Vestergaard P, Gram LF, Kragh-Sorensen P, Bech P, Reisby N, Bolwig TG. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol Ser. 1993;10:190-8.
173. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994;151(12):1735-9.
174. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord. 1996;39(1):1-6.
175. Biederman J, Thisted RA, Greenhill LL, Ryan ND. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry. 1995;56(3):87-93.
176. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409-32.
177. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1147-53.
178. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157(9):1445-52.
179. Quitkin FM, Stewart JW, McGrath PJ. Gender differences in treatment response. Am J Psychiatry. 2001;158(9):1531-3.
180. Quitkin FM, Stewart JW, McGrath PJ, Taylor BP, Tisminetzky MS, Petkova E, et al. Are there differences between women's and men's antidepressant responses? Am J Psychiatry. 2002;159(11):1848-54.
181. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308-15.
182. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51(3):237-54.
183. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger GC, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395-401.
184. Settle EC, Jr. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;59(Suppl 4): 32-6.
185. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995;56(Suppl 6):12-21.
186. Lineberry TW, Peters GE, Jr., Bostwick JM. Bupropion-induced erythema multiforme. Mayo Clin Proc. 2001;76(6):664-6.
187. DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry. 2002;63(Suppl 1):10-7.
188. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995;49(2):280-94.
189. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998;7(Suppl 1):24-32.
190. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58(Suppl 6): 26-31.
191. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin
192. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154(12):1760-2.
193. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Prenancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158(10):1728-30.
194. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull. 1990;26(3):311-5.
195. Lader MH. Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry. 1996;57(Suppl 2):39-44.
196. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. J Clin Psychiatry. 1987;48(6):244-5.
197. Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry. 2002;47(4):375-7.
198. Ehrentraut S, Rothenhausler HB, Gerbes AL, Rau HG, Thiel M, Schirren CA, et al. Acute liver failutre in nefazodone therapy? A case report [article in German]. Nervenarzt. 2002;73(7):686-9.
199. de Boer T, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology. 1988;27(4):399-408.
200. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(Suppl 4): 19-25.
201. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355(9207):911-8.
202. Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry. 1998;59(Suppl 4):5-14.
203. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;86(5):369-74.
204. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002;325(7376):1332-3.
205. Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J Clin Psychiatry. 1998;59:233-5.
206. Benson BE, Mathiason M, Dahl B, Smith K, Foley MM, Easom LA, et al. Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures. Am J Emerg Med. 2000;18(5):587-92.
207. de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg. 2001;56(4):258-61.
208. Harris CR, Gualtieri J, Stark G. Fatal bupropion overdose. J Toxicol Clin Toxicol. 1997;35(3):321-4.
209. Storrow AB. Bupropion overdose and seizure. Am J Emerg Med. 1994;12(2):183-4.
210. Spiller HA, Ramoska EA, Krenzelok EP, Sheen SR, Borys DJ, Villalobos D, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med. 1994;12(1):43-5.
211. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med. 2001;135(6):423-33.
212. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001;57(9):1583-8.
213. Dostert P, Benedetti MS, Poggest I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol. 1997;7(Suppl 1):S23-35.
214. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000;39(6):413-27.
215. Ohman D, Cherma MD, Norlander B, Bengstosson F. Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit. 2003;25(2):174-82.
216. Burrows GD, Maguire KP, Norman TR. Antidepressant efficiacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry. 1998;59(Suppl 14):4-7.
217. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry. 2000;61(Suppl 10):31-8.
218. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol. 2000;20(1):28-34.
219. Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther. 2001;70(3):261-9.
220. Andreoli V, Caillard V, Deo R, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol. 2002;22(4):393-9.
221. Montgomery S, Fuerguson JM, Schwartz GE. The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol. 2003;23(1):45-50.
222. Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178-84.
223. Bruhl AB, Kaffenberger T, Herwig U. Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychopharmacology. 2010;35(2):521-33.
224. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001;21(5):516-21.
225. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, et al. An open trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002;52(5):386-92.
226. Krishnan KR. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry. 2003;63(Suppl 11):25-9.
227. Rimon R, Le Greves P, Nyberg F, Heikkila L, Salmela L, Terenius L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry. 1984;19(4):509-16.
228. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010;25(2):95-102.
229. Fishback JA, Robson MJ, Xu YT, Matsumoto RR. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther. 2010;127:271-82.
230. Fox H, Gibas J. Synthetic tuberculostats. VII. Monoalkyl derivatives of isonicotinylhydrazine. J Org Chem. 1953;18:994-1002.
231. Selikoff IJ, Robitzek EH, Orenstein GG. Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. JAMA. 1952;150:973-80.
232. Loomers HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep. 1957;8:129-41.
233. Kline NS. Clinical experience with iproniazid (MARSILID). J Clin Exp Pyschopathol. 1958;19(Suppl 1):72-8.
234. Zeller EA, Barsky JR, Fouts W, et al. Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia. 1952;8:349-50.
235. Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O, Youdim MBH. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology. 2002;43(6):999-1005.
236. Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol. 1999;19(3):411-26.
237. Youdim MB, Aronson JK, Blau K, Green AR, Grahame-Smith DG. Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med. 1979;9(2):377-82.
238. Sherry-McKenna RL, Baker GB, Mousseau DD, Coutts RT, Dewhurst WG. 4-methyoxytranylcypromine, a monoamine oxidase inhibitor: effects on biogenic amines in rat brain following chronic administration. Biol Psychiatry. 1992;31(9):881-8.
239. Sherry RL, Rauw G, McKenna KF, Paetsch PR, Coutts RT, Baker GB. Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine. J Affect Disord. 2000;61(1-2):23-9.
240. Lang A, Geissler HE, Mutschler E. Determination and comparison of the plasma and urine concentrations in men given tranylcypromine stereoisomers [article in German]. Arzneimittelforschung. 1979;29(1):154-7.
241. Spahn-Langguth H, Hahn G, Mutschler E, Mohrke W, Langguth P. Enantiospecific highperformance liquid chromatographic assay with fluoroscence detection for the monoamine oxidase ihibitor tranylcypromine and its applicability in pharmacokinetic studies. J Chromatogr. 1992;584(2):229-37.
242. Livingston MG, Livingston HM. Monoamine oxidase inhibitors. An update on drug interactions. Drug Saf. 1996;14(4):219-27.
243. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226-47.
244. Guelfi JD, Payan C, Fermanian J, Pedarriosse AM, Manfredi R. Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. Br J Psychiatry. 1992;160:519-24.
245. Hilton SE, Maradit H, Moller HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatr Clin Neurosci. 1997;247(3):113-9.
246. van Vliet IM, Westenberg HG, Den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl). 1993;112(4):483-9.
247. Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl). 1992;106(Suppl):S6-14.
248. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatmentrefractory depression. Am J Psychiatry. 1993;150(1):118-23.
249. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45(2):129-37.
250. McGrath PJ, Stewart JW, Harrison WM, Ocepek-Welikson K, Rabkin JG, Nunes EN, et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol. 1992;12(3):197-202.
251. Vallejo J, Gasto C, Catalan R, Salamero M. Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry. 1987;151:639-42.
252. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148(7):910-6.
253. Georgotas A, McCue RE, Hapworth W, Friedman E, Kim OM, Welkowitz J, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry. 1986;21(12):1155-66.
254. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry. 1990;47(10):935-41.
255. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185-219.
256. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry. 1985;142(5):619-23.
257. Roose SP, Glassman AH, Walsh BT, Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry. 1986;143(3):345-8.
258. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149(2):195-8.
259. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992;49(4):290-300.
260. Stein G. Drug treatment of the personality disorders. Br J Psychiatry. 1992;161:167-84.
261. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150(12):1843-8.
262. Nurnberg HG, Levine PE. Spontaneous remission of MAOI-induced anorgasmia. Am J Psychiatry. 1987;144(6):805-7.
263. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese (letters to the editor). Lancet. 1963;2:733-4.
264. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967;113:349-65.
265. Hyman S. Toxic side effects of psychotropic medications and their management. In: Hyman S, Tesar G, editors. Manual of psychiatric emergencies. 3rd ed. Boston: Little Brown 1994. p. 204-17; 304-22.
266. Insel TR, Roy BF, Cohen RM, Murphy DL. Possible development of the serotonin syndrome in man. Am J Psychiatry. 1982;139(7):954-5.
267. Creelman WL, Ciraulo DA. Monoamine oxidase inhibitors (MAOIS). In: Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL, editors. Drug interactions in psychiatry. 2nd ed. Baltimore, MD: Williams & Wilkins; 1995. p. 430.
268. Linden CH, Rumack BH, Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med. 1984;13(12):1137-44.
269. Vartzopoulos D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry. 1991;158:856-7.
270. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven; 1995. p. 1081.
271. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(Suppl 13):23-9.
272. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry. 2000;61(Suppl 2):10-2.
273. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry. 1999;60(1):45-9.
274. Debonnel G, Gobbi G, Turcotte J, et al., editors. The a2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; San Juan, Puerto Rico.
275. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression. Biol Psychiatry. 2002;51:183-8.
276. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol. 1996;16:80-1.
277. Bodkin JA, Lasser RA, Wines JD, Jr., Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58(4):137-45.
278. Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7:73-5.
279. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000;61(6):403-8.
280. Nelson JC, Mazure CM, Bowers MB, Jr., Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48(4):303-7.
281. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151(9):1372-4.
282. Rothschild BS. Fluoxetine-nortiptyline therapy of treatment-resistant major depression in a geriatric patient. J Geriatr Psychiatry Neurol. 1994;7(3):137-8.
283. Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatmentresistant depression. Depress Anxiety. 1997;5(2):84-90.
284. de Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry. 1981;138:252-6.
285. de Montigny C, Cournoyer G, Morissette R, Langlois R, Caille G. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepresant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry. 1983;40(12):1327-34.
286. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50(5):387-93.
287. Gray EG. Severe depression: a patient's thoughts. Br J Psychiatry. 1983;143:319-22.
288. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch Gen Psychiatry. 1983;40(12):1335-42.
289. Graham PM. Drug combination for chronic depression. Br J Psychiatry. 1984;145:214.
290. Pope HG, Jr., McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry. 1988;145:1292-4.
291. Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, et al. Placebocontrolled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry. 1995;166(1):80-6.
292. Bauer M, Zaninelli R, Muller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Psychopharmacol. 1999;19(2):164-71.
293. Peterson EA, Nelson K. How to meet your clients' spiritual needs. J Psychosoc Nurs Ment Health Serv. 1987;25(5):34-9.
294. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60(4):256-9.
295. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009; 166(9):980-91.
296. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978-86.
297. Papakostas GI. Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics. CNS Spectr. 2007;12(12 Suppl 22):10-2.
298. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-53.
299. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-65.
300. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astrom M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetinecontrolled study. J Clin Psychiatry. 2009;70(4):526-39.
301. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005;66(Suppl 8):30-40.
302. Jacobsen FM. A possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52:217-20.
303. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54:269-71.
304. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors in severe treatment-refractory depression. S Afr Med J. 1997;87(Suppl 4): 534-7.
305. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol. 1998;18:465-9.
306. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62(6):448-52.
307. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59(12):664-8.
308. Patrick KS, Mueller RA, Gualtieri CT, Breese GR. Pharmacokinetics and actions of methylphenidate. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven; 1987. p. 1387-95.
309. Wharton RN, Perel JM, Dayton PG, Malitz SM. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry. 1971;127:1619-25.
310. Fawcett JA, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Psychopharmacol. 1991;11:127-32.
311. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry. 1996;57(2):72-6.
312. Bader GM, Hawley JM, Short DD. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J Clin Psychopharmacol. 1998;18(3):255-6.
313. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety. 1998;7:89-91.
314. Postolache TT, Rosenthal RN, Hellerstein DJ, Aromin R, Kelton GM, Muran JC, et al. Early augmentation of sertraline with methylphenidate. J Clin Psychiatry. 1999;60(2):123-4.
315. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry. 2001;9(3):298-303.
316. Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:781-823.
317. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry. 2002;59(5):409-16.
318. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61(5):378-81.
319. Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy [letter]. J Clin Psychopharmacol. 2003;23(2):207-9.
320. Prange AJ, Jr., et al. Hormonal alteration of imipramine response: a review. In: Sachar EJ, editor. Hormones, behavior, and psychopathology. New York: Raven; 1976.
321. Wheatley D. Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry. 1972;26:229-33.
322. Tsutsui S, Yamazaki Y, Namba T, Tsushima M. Combined therapy of T3, and antidepressants in depression. J Int Med Res. 1979;7(2):138-46.
323. Earle BV. Thyroid hormone and tricyclic antidepressants in resistant depressions. Am J Psychiatry. 1970;126(11):1667-9.
324. Ogura C, Okuma T, Uchida Y, Imai S, Yogi H. Combined thyroid (triodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn. 1974;28(3):179-86.
325. Goodwin FK, Prange A, Post R, Muscettola G, Lipton MA. Potentiation of antidepresant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry. 1982;139(1):34-8.
326. Joffe RT, Levitt AJ, Bagby RM, MacDonald C, Singer W. Predictors of response to lithium and triiodothyronine: augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry. 1993;163:574-8.
327. Crowe D, Collins JP, Rosse RB. Thyroid hormone supplementation of fluoxetine treatment [letter]. J Clin Psychopharmacol. 1990;10:150-1.
328. Gupta S, Masand P, Tanquary JF. Thyroid hormone supplementation of fluoxetine in the treatment of major depression. Br J Psychiatry. 1991;159:866-7.
329. Joffe RT. Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry. 1992;37:48-50.
330. Gitlin MJ, Weiner H, Farbanks L, Hershman JM, Friedfeld N. Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord. 1987;13(3):267-72.
331. Targum SD, Greenberg RD, Harmon RL, Kessler K, Salerian AJ, Fram DH. Thyroid hormone and the TRH stimulation test in refractory depression. J Clin Psychiatry. 1984;45(8):345-6.
332. Spoov J, Lahdelma L. Should thyroid augmentation precede lithium augmentation - a pilot study. J Affect Disord. 1998;49:235-9.
333. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology. 1998;18(6):444-55.
334. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001;158(10):1617-22.
335. Pope HG, Jr., Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(1):105-11.
336. de Novaes Soares C, Almeida O, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebocontrolled trial. Arch Gen Psychiatry. 2001;58(6):529-34.
337. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414-20.
338. Rasgon NL, Altshuler LL, Fairbanks LA, Dunkin JJ, Davtyan C, Elman S, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry. 2002;63(Suppl 7):745-8.
339. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol. 1995;102:475-84.
340. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930-3.
341. Ahokas A, Kaukoranta J, Aito M. Effect of oestradiol on postpartum depression. Psychopharmacology. 1999;146:108-10.
342. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol. 1977;4:31-47.
343. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract. 1981;31:134-40.
344. Pearce J, Hawton K, Blake F, Barlow D, Rees M, Fagg J, et al. Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study. J Psychosom Res. 1997;42:177-86.
345. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61(5):676-97.
346. Montgomery JC, Brincat M, Tapp A, Appleby L, Versi E, Fenwick PBC, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet. 1987;1:297-9.
347. Kaliber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550-4.
348. Haines CJ, Yim SF, Chung TKH, Lam CWK, Lau EWC, Ng MHL, et al. A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas. 2003;44:207-14.
349. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 1997;5:97-106.
350. Sheline YI, Pieper CF, Barch DM, Welsh-Boehmer K, McKinstry RC, MacFall JR, et al. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry. 2010;67(3):277-85.
351. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab. 2003;17(1):139-47.
352. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349(6):535-45.
353. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254-63.
354. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523-34.
355. Rogoz Z, Skuza G, Daniel WA, Wojcikowski J, Dudek D, Wrobel A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep. 2007;59(6):778-84.
356. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol. 2003;18(2):93-6.
357. Schultz V, Haensel R, Tyler VE, editors. Rational phytotherapy. 3rd ed. Berlin: Springer; 1998.
358. Assemi M. Herbs affecting the central nervous system: gingko, kava, St. John's wort, and valerian. Clin Obstet Gynecol. 2001;44(4):824-35.
359. De Smet P. Herbal remedies. N Engl J Med. 2002;347(25):2046-56.
360. Bilia AR, Gallori S, Vincieri FF. St. John's wort and depression: efficacy, safety and tolerability- an update. Life Sci. 2002;70(26):3077-96.
361. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ. 1999;319(7224):1534-8.
362. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136(1):42-53.
363. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ. 2000;321(7260):536-9.
364. Gaster B, Holroyd J. St John's wort for depression: a systematic review. Arch Intern Med. 2000;160(2):152-6.
365. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002;159(8):1361-6.
366. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatr Neurol. 1999;12(1):7-10.
367. Prost N, Tichadou L, Rodor F, Nguyen N, David JM, Jean-Pastor MJ. [St. Johns wort-venlafaxine interaction]. Presse Med. 2000;29(23):1285-6.
368. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001;134(8):1601-8.
369. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54(4):349-56.
370. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother. 2000;34(9):1013-6.
371. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation. 2001;71(2):239-41.
372. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet. 2000;355(9203):576-7.
373. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70(4):317-26.
374. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66(4):338-45.
375. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156(5):675-82.
376. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313(7052):253-8.
377. Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berl). 2002;164(3):301-8.
378. Spira JL. Comparison of St John's Wort and imipramine. Study design casts doubt on value of St John's wort in treating depression. BMJ. 2001;322(7284):493; author reply 4.
379. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807-14.
380. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76(5):1158S-61S.
381. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl. 1994;154:15-8.
382. Bressa GM. S-adenoxyl-methionine (SAMe) as antidepressant: metanalysis of clinical studies. Acta Neurol Scand. 1994;154:7-14.
383. Pancheri P, Racagni G, Delle Chiaie R, Popoli M. Recent experimental and clnical findings on the efficacy and safety of ademetionine in the pharmacological treatment of depression. G Ital Psicopat. 1997;3:1-23.
384. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002;76(5):1172S-6S.
385. Fava M, Giannelli A, Rapisarda V, Patralia A, Guaraldi GP. Rapidity of onset of the antidepressant effect of parental S-adenosyl-L-methionine. Psychiatr Res. 1995;56:295-7.
386. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 5):18-22.
387. Hibbeln JR. Fish consumption and major depression. Lancet. 1998;351(9110):1213.
388. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord. 1996;38(1):35-46.
389. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord. 1998;48(2-3):149-55.
390. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinic symptoms of depression. Lipids. 1996;31(Suppl):157-61.
391. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59:913-9.
392. Calabrese JR, Rapport DJ, Shelton MD. Fish oils and bipolar disorder: a promising but untested treatment [commentary]. Arch Gen Psychiatry. 1999;56(5):413-4.
393. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407-12.
394. Stoll AL, Marangell LB. In reply [commentary]. Arch Gen Psychiatry. 1999;56(5):415-6.
395. Freeman MP. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 5):7-11.
396. Waal HJ. Propranolol-induced depression. Br Med J. 1967;2(5543):50.
397. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351-7.
398. Steffensmeier JJ, Ernst ME, Kelly M, Hartz AJ. Do randomized controlled trials always trump case reports? A second look at propranolol and depression. Pharmacotherapy. 2006;26(2):162-7.
399. Dunn NR, Freemantle SN, Mann RD. Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression. Br J Clin Pharmacol. 1999;48(2):230-3.
400. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478-84.
401. Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL, editors. Drug interactions in psychiatry. 2nd ed. Baltimore, MD: Williams & Wilkins; 1995.
402. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol. 1999;19(5 Suppl 1):23S-35S.
403. Burke WJ, McArthur-Miller DA. Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. J Clin Psychiatry. 2001;62(Suppl 22): 38-42.
404. Dinan TG. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. J Clin Psychiatry. 2001;62(Suppl 22):48-52.
405. Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs. 2001;61(15):2221-30.
406. de Klerk E. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2001;62(Suppl 22):43-7.
407. Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9(6):397-402.
408. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999;60(3):191-3.